Valbiotis Announces the Implementation of the TOTUM•63 Mode of Action Clinical Study by INAF1 at Laval University in Quebec City, in Partnership With Nestlé Health Science
Regulatory News:
Valbiotis (FR0013254851 – ALVAL, PEA/SME eligible), a Research and Development company committed to scientific innovation for preventing and combating metabolic diseases, announces the implementation of the TOTUM•63 mode of action clinical study by the Institute of nutrition and functional foods (INAF) at Laval University in Quebec City, in partnership with Nestlé Health Science.
This study, co-designed by Valbiotis in conjunction with INAF and Nestlé Health Science experts as part of the global strategic partnership, will include 20 volunteers and will explore the mechanism of action of TOTUM•63 in humans. It will provide additional data to strengthen the scientific communication and support the commercialization of TOTUM•63. Scheduled to begin in the 4th quarter of 2021, it will be conducted under the scientific supervision of André MARETTE, Professor at the Laval University Faculty of Medicine and researcher at INAF.
Murielle CAZAUBIEL, Chief Medical, Regulatory and Industrial Affairs Officer at Valbiotis, member of the Board of Directors, comments: "This very ambitious study will explore the mode of action of TOTUM•63, a multitarget active substance, in humans. It is the result of a high level of collective work with experts from INAF and Nestlé Health Science, whom we would like to thank for their commitment to this process. INAF is a key player in nutrition and metabolic sciences in North America, particularly in Canada, a country leading the way in the regulation of natural health products. This collaboration is an undeniable asset for the completion of TOTUM•63 development under the global strategic partnership with Nestlé Health Science. And this affiliation with the Canadian scientific ecosystem reflects our commitment to develop R&D activities in North America, the epicenter of global research and a leading commercial market in the field of metabolic diseases."
The TOTUM•63 mode of action clinical study will explore, in humans, the main mode of action hypotheses resulting from preclinical work. It will include 20 overweight or obese volunteers with associated metabolic abnormalities. With a large number of scientific objectives, the protocol will evaluate the effect of TOTUM•63 administration for 8 weeks on numerous mechanistic parameters involved in the pathophysiology of prediabetes and type 2 diabetes, through in-depth physiological investigations: mainly intestinal absorption of nutrients, metabolomics, inflammation, composition of the intestinal microbiota and gastrointestinal hormones (incretins, including GLP-1).
Prof. André MARETTE, Professor at the Laval University Faculty of Medicine (Quebec City) and researcher at INAF, and scientific advisor of the study comments: "This scientific collaboration between our two organizations makes perfect sense, as Valbiotis' approach is fully in line with INAF's research. As a member of Valbiotis' Scientific and Medical Board for the past 4 years, I am well aware of the relevance of their R&D in the field of metabolic disease and I am convinced of the multitarget approach of its active substances. This is what we will explore in humans, with this study on the mode of action of TOTUM•63. With the collaboration of Prof. Marie-Claude VOHL, expert in genomics applied to nutrition and metabolic health, we will be able to identify the mechanisms of action of TOTUM•63 on subjects with overweight or obesity associated with metabolic abnormalities, including metabolomic and (meta)genomic signatures related to expected metabolic health effects such as inflammation and gastrointestinal functions.We at INAF look forward to bringing our expertise and our investigative resources to the service of this exciting project."
The study, designed to boost the scientific and commercial value of TOTUM•63, is part of the development plan established with Nestlé Health Science under the global strategic partnership for TOTUM•63. It will be the subject of milestone payments, dedicated in particular to its financing. Its launch is planned for the fourth quarter of 2021.
To support this scientific collaboration and the development of Valbiotis' R&D activities in North America, the Company is opening a subsidiary, with a full-time employee responsible for scientific coordination starting in September. The research project carried out under this collaboration will be eligible for the Canadian Scientific Research and Experimental Development (SR&ED) program (system equivalent to the French research tax credit).
About INAF
Created in the early 2000s to address the challenges of sustainable nutrition and the prevention of metabolic diseases, INAF brings together some 100 researchers in bio-food, health and social sciences from 14 universities and scientific institutions in Québec. Its multidisciplinary approach and the quality of the projects it coordinates have earned it a reputation for scientific excellence on the North American continent.
About TOTUM•63
TOTUM•63 is a unique and patented combination of 5 plant extracts that targets the pathophysiological mechanisms of type 2 diabetes.
TOTUM•63 has already been shown to be safe and effective in healthy volunteers in a Phase I/II clinical study. Results from a randomized, placebo-controlled, international Phase II study showed that when compared to the placebo, TOTUM•63 reduced fasting blood glucose and 2-hour blood glucose levels, two risk factors for type 2 diabetes.
In these subjects, who were also abdominally obese, TOTUM•63 also significantly reduced body weight and waist circumference.
TOTUM•63 benefits from intellectual property validated by patents in the world's leading markets: Europe (covering 39 countries), the United States, Russia, China, Japan, Mexico, Indonesia, Israel, South Africa, New Zealand and national phases are still underway in a dozen other countries including Brazil and Australia. Production capacity for TOTUM•63 has been validated in accordance with North American and European standards. TOTUM•63 already has marketing authorizations related to its status in Europe.
In February 2020, Valbiotis signed a long-term global strategic partnership with Nestlé Health Science for the development and worldwide commercialization of TOTUM•63. This unique partnership in the field of Health Nutrition foresees the marketing of TOTUM•63 by Nestlé Health Science on a worldwide scale, possibly before obtaining a medical clearance depending on the area. They will also fund the final stages of development of TOTUM•63.
About Valbiotis
Valbiotis is a Research & Development company committed to scientific innovation for the treatment and prevention of metabolic diseases in response to unmet medical needs.
Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, based on a multi-target approach enabled by the use of plant-based ingredients.
Its products are intended to be licensed to players in the health sector.
Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in Quebec City (Canada).
Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has also been awarded "Young Innovative Company" status and has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.
For more information about Valbiotis, please visit: www.valbiotis.com.
Name: Valbiotis
ISIN code: FR0013254851
Mnemonic code: ALVAL
EnterNext© PEA-PME 150
This press release contains forward-looking statements about Valbiotis' objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to the company at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be reconsidered based on changes in economic conditions and financial markets, as well as a certain number of risks and uncertainties, including those described in the Valbiotis registration document, filed with the French Financial Markets Regulator (AMF) on 31 July 2020 (application number R 20-018). This document is available on the Company's website (www.valbiotis.com).
This press release, as well as the information contained herein, does not constitute an offer to sell or subscribe to, or a solicitation to purchase or subscribe to, Valbiotis' shares or securities in any country.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210628005485/en/
Contact information
Corporate communication / Valbiotis
Carole Rocher / Marc Delaunay
+33 5 46 28 62 58
media@valbiotis.com
Financial communication / Actifin
Stéphane Ruiz
+33 1 56 88 11 14
sruiz@actifin.fr
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
HCLTech and Equinor Expand Digital Collaboration2.7.2025 14:08:00 EEST | Press release
HCLTech, a global technology leader, and Equinor, Europe's largest energy supplier and a pioneer in renewables and low-carbon solutions, have expanded their IT collaboration to support the next phase of Equinor’s digital transformation. This expanded relationship will cover Equinor’s IT landscape across several key strategic areas. HCLTech will support Equinor as it accelerates its digital transformation by: Accelerating its cloud migration and standardizing services across operations Enhancing its cyber resilience and network performance Improving workplace experience through automation Enabling advanced user experiences with technologies like augmented reality (AR) "We’re pleased to continue our long-standing collaboration with Equinor," said Sandeep Kumar Saxena, Executive Vice President, HCLTech. "This collaboration reflects our shared commitment to innovation and sustainability.” Over the past decade, HCLTech has been a trusted advisor to Equinor, supporting the company’s global e
Wizz Air Tops Major Airline Emissions Rankings2.7.2025 12:00:00 EEST | Press release
Wizz Air is the world's most emissions-efficient airline in new rankings released today by Cirium, the aviation analytics firm. The Cirium Flight Emissions Review ranks the top 20 airlines globally, through a consistent benchmark for flight emissions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702342529/en/ The top 20 Major airlines globally, ranked by lowest CO2/ASK Wizz Air, the Hungary-based ultra-low-cost airline emits an industry low of 53.9 grams of CO₂ per Available Seat Kilometer (ASK)*, followed by Frontier Airlines (54.4 grams) and Pegasus (57.1 grams) according to the report. The rankings provide the aviation industry with verified comparable data on an equal playing field as the sector advances toward Net Zero by 2050 commitments. The rankings performance use Cirium's EmeraldSky platform, which achieved ISAE 3000 Reasonable Assurance from PricewaterhouseCoopers (PwC) and official accreditation from the Roc
L&T Technology Services Chosen by TRATON GROUP as Strategic Engineering Partner in Global R&D Transformation2.7.2025 11:59:00 EEST | Press release
L&T Technology Services (BSE: 540115, NSE: LTTS), today announced that it has been chosen by the TRATON GROUP, one of the world’s leading manufacturers of commercial vehicles, as a strategic engineering partner. This collaboration in LTTS’ Mobility segment will support TRATON’s roadmap to build a unified, future-ready product-development platform that delivers scale, speed, and sustainable mobility solutions worldwide. TRATON is reshaping its global R&D ecosystem to unlock cross-brand synergies while expanding the share of battery-electric vehicles in line with its 2029 profitability and sustainability targets. LTTS’ selection will see the company provide engineering support, from mechanical and software engineering to digital systems integration - across key development hubs in Sweden, Germany, the United States, Poland, and India. The collaboration positions LTTS to deepen existing workstreams and pursue new programs across TRATON’s brands, spanning software-defined vehicle architect
Nexo Becomes First-Ever Digital Wealth Platform of the DP World Tour, Launches Nexo Championship2.7.2025 11:30:00 EEST | Press release
Nexo, the premier digital assets wealth platform, has signed a three-year landmark partnership with the DP World Tour, becoming an Official Marketing Partner and the Tour’s Official Digital Wealth Platform through 2027. This agreement marks the first-ever multi-year partnership between a digital assets company and a major global golf tour — a historic convergence of crypto and golf — reflecting both organizations’ shared commitment to performance, innovation, and a global outlook. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250702770847/en/ Nexo becomes the first-ever Official Digital Wealth Platform of the DP World Tour. Nexo has also become the Title Partner of the newly renamed Nexo Championship — previously the Scottish Championship — taking place from August 7–10, 2025. The tournament is set at the Trump International Golf Links in Aberdeenshire, which has earned a reputation as one of the finest modern links courses
Ferring ADAPT-1 Trial Builds on Dosing Evidence for Follitropin Delta2.7.2025 11:00:00 EEST | Press release
Follitropin delta starting dose of 15 micrograms (µg)/day has comparable efficacy and safety as a starting dose of 225 International Units (IU)/day of follitropin alfa for ovarian stimulation in vitro fertilisation (IVF)/intracytoplasmic sperm injection (ICSI) gonadotrophin-releasing hormone (GnRH) antagonist protocol cycles. This is the key finding of a trial presented today at the European Society of Human Reproduction and Embryology (ESHRE) Congress in Paris and published in Human Reproduction. These data build on previous studies which have established an estimated point of clinical correspondence for 10 µg follitropin delta to 150 IU follitropin alfa in this class of medications.1,2 The ADAPT-1 trial was a multicentre, randomised, assessor-blind study involving 300 women aged 18-40 years undergoing IVF or ICSI.3 The trial compared the efficacy and safety of follitropin delta and follitropin alfa using conventional dosing regimens with a primary endpoint of number of oocytes retrie
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom